
Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia.
What Happened: Minerva secured a securities purchase agreement with institutional investors providing up to $200 million in gross proceeds through a private placement. The arrangement includes $80 million in immediate funding through Series A preferred stock, plus up to $80 million more if Tranche A warrants are fully exercised.